XAIR
Beyond Air, Inc.
Price Chart
Latest Quote
$1.15
Current Price| Previous Close | $1.19 |
| Open | $1.16 |
| Day High | $1.24 |
| Day Low | $1.13 |
| Volume | 211,097 |
Stock Information
| Shares Outstanding | 8.53M |
| Total Debt | $13.80M |
| Cash Equivalents | $10.70M |
| Revenue | $5.80M |
| Net Income | $-36.70M |
| Sector | Healthcare |
| Industry | Medical Devices |
| Market Cap | $9.81M |
| EPS (TTM) | $-5.56 |
| Exchange | NCM |
đ Custom Metrics & Score
Score: 14/42| Debt to Equity | 0.86 |
| Debt to Earnings | -7.03 |
| Current Ratio | 3.20 |
| Quick Ratio | 1.56 |
| Profit Margin | -1258.43% |
| Return on Equity | -343.26% |
| Avg FCF Growth | 19.85% |
| FCF Yield | -449.34% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $1.15 | 217,900 |
| 2026-01-30 | $1.19 | 323,000 |
| 2026-01-29 | $1.23 | 358,200 |
| 2026-01-28 | $1.27 | 369,900 |
| 2026-01-27 | $1.35 | 665,900 |
| 2026-01-26 | $1.46 | 400,700 |
| 2026-01-23 | $1.62 | 703,600 |
| 2026-01-22 | $1.77 | 751,900 |
| 2026-01-21 | $1.82 | 1,349,700 |
| 2026-01-20 | $1.95 | 4,345,700 |
| 2026-01-16 | $1.70 | 6,445,300 |
| 2026-01-15 | $1.72 | 4,468,200 |
| 2026-01-14 | $1.88 | 20,228,900 |
| 2026-01-13 | $2.19 | 408,605,500 |
| 2026-01-12 | $0.88 | 102,200 |
| 2026-01-09 | $0.88 | 171,800 |
| 2026-01-08 | $0.95 | 357,900 |
| 2026-01-07 | $0.83 | 114,100 |
| 2026-01-06 | $0.79 | 78,600 |
| 2026-01-05 | $0.82 | 215,800 |
About Beyond Air, Inc.
Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through three segments: Beyond Air, Beyond Cancer, and NeuroNos. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM) at home. In addition, the company develops ultra-high concentration (UNO) that is in Phase 1 clinical trial to treat multiple solid and cutaneous tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions and autism spectrum disorder. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.
đ° Latest News
Top Midday Decliners
MT Newswires âĸ 2026-01-14T19:10:49ZTop Midday Gainers
MT Newswires âĸ 2026-01-13T18:54:06ZBC-Most Active Stocks
Associated Press Finance âĸ 2026-01-13T15:30:17ZBeyond Air Inc (XAIR) Q2 2026 Earnings Call Highlights: Strong Revenue Growth Amid Operational ...
GuruFocus.com âĸ 2025-11-11T05:02:32Z
Astera Labs Among 3 Leading Growth Companies With Strong Insider Ownership
Simply Wall St. âĸ 2025-08-27T11:40:25Z
Beyond Air Inc (XAIR) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic Expansion ...
GuruFocus.com âĸ 2025-08-13T07:11:48Z
Beyond Air, Inc. (XAIR) Reports Q1 Loss, Lags Revenue Estimates
Zacks âĸ 2025-08-12T21:35:02Z
AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Beats Revenue Estimates
Zacks âĸ 2025-08-07T22:20:01Z
Here's Why Beyond Air (XAIR) Could be Great Choice for a Bottom Fisher
Zacks âĸ 2025-06-26T13:55:01Z
Beyond Air Full Year 2025 Earnings: EPS Beats Expectations, Revenues Lag
Simply Wall St. âĸ 2025-06-19T18:24:15Z
Income Statement (Annual)
Revenue
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Reconciled Cost Of Revenue | $5,368,000 | $2,466,000 | $555,000 | $0 |
| Cost Of Revenue | $5,368,000 | $2,466,000 | $555,000 | $0 |
| Total Revenue | $3,705,000 | $1,159,000 | $0 | $0 |
| Operating Revenue | $3,705,000 | $1,159,000 | $0 | $0 |
Expenses
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Interest Expense | $3,019,000 | $2,912,000 | $30,000 | $775,000 |
| Total Expenses | $48,242,000 | $64,166,000 | $52,059,000 | $30,210,000 |
| Other Income Expense | $-923,000 | $1,625,000 | $-7,312,000 | $-13,075,000 |
| Other Non Operating Income Expenses | $9,000 | $-767,000 | $-7,863,000 | $-2,435,000 |
| Net Non Operating Interest Income Expense | $-3,019,000 | $-2,912,000 | $-30,000 | $-775,000 |
| Interest Expense Non Operating | $3,019,000 | $2,912,000 | $30,000 | $775,000 |
| Operating Expense | $42,874,000 | $61,700,000 | $51,504,000 | $30,210,000 |
| General And Administrative Expense | $26,017,000 | $37,337,000 | $34,694,000 | $18,408,000 |
Income & Earnings
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-46,625,000 | $-60,242,000 | $-55,816,000 | $-43,177,000 |
| Net Interest Income | $-3,019,000 | $-2,912,000 | $-30,000 | $-775,000 |
| Normalized Income | $-45,693,000 | $-62,634,000 | $-56,367,000 | $-32,537,000 |
| Net Income From Continuing And Discontinued Operation | $-46,625,000 | $-60,242,000 | $-55,816,000 | $-43,177,000 |
| Total Operating Income As Reported | $-44,537,000 | $-63,006,000 | $-52,059,000 | $-40,710,000 |
| Net Income Common Stockholders | $-46,625,000 | $-60,242,000 | $-55,816,000 | $-43,177,000 |
| Net Income | $-46,625,000 | $-60,242,000 | $-55,816,000 | $-43,177,000 |
| Net Income Including Noncontrolling Interests | $-48,479,000 | $-64,295,000 | $-59,401,000 | $-44,060,000 |
| Net Income Continuous Operations | $-48,479,000 | $-64,295,000 | $-59,401,000 | $-44,060,000 |
| Pretax Income | $-48,479,000 | $-64,295,000 | $-59,401,000 | $-44,060,000 |
| Special Income Charges | $-3,185,000 | $0 | $0 | $-10,500,000 |
| Operating Income | $-44,537,000 | $-63,007,000 | $-52,059,000 | $-30,210,000 |
| Gross Profit | $-1,663,000 | $-1,307,000 | $-555,000 | $0 |
Per Share Metrics
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Diluted EPS | $-13.80 | $-36.40 | $-37.20 | $-33.60 |
| Basic EPS | $-13.80 | $-36.40 | $-37.20 | $-33.60 |
Other
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-40,957,000 | $-61,423,000 | $-58,752,000 | $-32,057,000 |
| Total Unusual Items | $-932,000 | $2,392,000 | $551,000 | $-10,640,000 |
| Total Unusual Items Excluding Goodwill | $-932,000 | $2,392,000 | $551,000 | $-10,640,000 |
| Reconciled Depreciation | $3,571,000 | $2,352,000 | $1,170,000 | $588,000 |
| EBITDA (Bullshit earnings) | $-41,889,000 | $-59,031,000 | $-58,201,000 | $-42,697,000 |
| EBIT | $-45,460,000 | $-61,383,000 | $-59,371,000 | $-43,285,000 |
| Diluted Average Shares | $3,385,326 | $1,658,009 | $1,498,681 | $1,283,411 |
| Basic Average Shares | $3,385,326 | $1,658,009 | $1,498,681 | $1,283,411 |
| Diluted NI Availto Com Stockholders | $-46,625,000 | $-60,242,000 | $-55,816,000 | $-43,177,000 |
| Minority Interests | $1,854,000 | $4,053,000 | $3,585,000 | $882,000 |
| Tax Provision | $0 | $0 | $0 | $0 |
| Gain On Sale Of Ppe | $-738,000 | $0 | - | - |
| Other Special Charges | $2,447,000 | $598,000 | $7,863,000 | $10,500,000 |
| Gain On Sale Of Security | $2,253,000 | $2,392,000 | $551,000 | $-140,000 |
| Research And Development | $16,857,000 | $24,363,000 | $16,810,000 | $11,802,000 |
| Selling General And Administration | $26,017,000 | $37,337,000 | $34,694,000 | $18,408,000 |
| Other Gand A | $26,017,000 | $37,337,000 | $34,694,000 | $18,408,000 |
Balance Sheet (Annual)
Assets
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Net Tangible Assets | $12,361,000 | $23,621,000 | $36,283,000 | $70,867,000 |
| Total Assets | $30,062,000 | $56,961,000 | $68,749,000 | $99,199,000 |
| Total Non Current Assets | $14,044,000 | $13,025,000 | $9,340,000 | $6,254,000 |
| Other Non Current Assets | $103,000 | $113,000 | $212,000 | $207,000 |
| Goodwill And Other Intangible Assets | $1,222,000 | $1,427,000 | $1,632,000 | $1,837,000 |
| Other Intangible Assets | $1,222,000 | $1,427,000 | $1,632,000 | $1,837,000 |
| Current Assets | $16,018,000 | $43,936,000 | $59,410,000 | $92,945,000 |
| Other Current Assets | $203,000 | $277,000 | $338,000 | $508,000 |
| Restricted Cash | $231,000 | $230,000 | $7,610,000 | $9,988,000 |
| Prepaid Assets | $5,390,000 | $6,286,000 | $3,800,000 | $1,253,000 |
| Inventory | $2,417,000 | $2,127,000 | $1,129,000 | $350,000 |
| Receivables | $860,000 | $548,000 | $651,000 | $604,000 |
| Taxes Receivable | $150,000 | $229,000 | $231,000 | $282,000 |
| Accounts Receivable | $710,000 | $319,000 | $0 | - |
| Cash Cash Equivalents And Short Term Investments | $6,917,000 | $34,468,000 | $45,882,000 | $80,242,000 |
| Cash And Cash Equivalents | $4,665,000 | $11,378,000 | $29,158,000 | $80,242,000 |
| Other Receivables | - | - | $420,000 | $322,000 |
Debt
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Net Debt | $5,141,000 | $4,143,000 | - | - |
| Total Debt | $11,688,000 | $17,837,000 | $3,592,000 | $3,487,000 |
| Long Term Debt And Capital Lease Obligation | $10,683,000 | $16,619,000 | $2,441,000 | $2,279,000 |
| Long Term Debt | $9,197,000 | $14,721,000 | $120,000 | $200,000 |
| Current Debt And Capital Lease Obligation | $1,005,000 | $1,218,000 | $1,151,000 | $1,208,000 |
| Current Debt | $609,000 | $800,000 | $775,000 | $927,000 |
| Other Current Borrowings | $609,000 | $800,000 | $775,000 | $927,000 |
Liabilities
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $15,721,000 | $29,775,000 | $26,721,000 | $20,990,000 |
| Total Non Current Liabilities Net Minority Interest | $10,721,000 | $18,208,000 | $6,941,000 | $10,278,000 |
| Derivative Product Liabilities | $38,000 | $1,589,000 | $0 | - |
| Current Liabilities | $5,000,000 | $11,567,000 | $19,780,000 | $10,712,000 |
| Other Current Liabilities | $223,000 | $274,000 | $183,000 | $83,000 |
| Current Deferred Liabilities | $0 | $138,000 | $0 | - |
| Payables And Accrued Expenses | $3,772,000 | $9,937,000 | $18,446,000 | $9,421,000 |
| Payables | $1,950,000 | $1,948,000 | $2,016,000 | $1,129,000 |
| Accounts Payable | $1,950,000 | $1,948,000 | $2,016,000 | $1,129,000 |
| Other Non Current Liabilities | - | - | $4,500,000 | $7,999,000 |
| Tradeand Other Payables Non Current | - | - | - | $8,000,000 |
| Other Payable | - | - | - | $4,000,000 |
Equity
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Common Stock Equity | $13,583,000 | $25,048,000 | $37,915,000 | $72,704,000 |
| Total Equity Gross Minority Interest | $14,341,000 | $27,186,000 | $42,028,000 | $78,209,000 |
| Stockholders Equity | $13,583,000 | $25,048,000 | $37,915,000 | $72,704,000 |
| Gains Losses Not Affecting Retained Earnings | $-60,000 | $-15,000 | $53,000 | $96,000 |
| Other Equity Adjustments | $-60,000 | $-15,000 | $53,000 | $96,000 |
| Retained Earnings | $-286,322,000 | $-239,697,000 | $-179,455,000 | $-123,639,000 |
Other
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Ordinary Shares Number | $4,128,536 | $2,295,041 | $1,536,929 | $1,493,308 |
| Share Issued | $4,128,536 | $2,295,041 | $1,536,929 | $1,493,308 |
| Tangible Book Value | $12,361,000 | $23,621,000 | $36,283,000 | $70,867,000 |
| Invested Capital | $23,389,000 | $40,569,000 | $38,810,000 | $73,831,000 |
| Working Capital | $11,018,000 | $32,369,000 | $39,630,000 | $82,233,000 |
| Capital Lease Obligations | $1,882,000 | $2,316,000 | $2,697,000 | $2,360,000 |
| Total Capitalization | $22,780,000 | $39,769,000 | $38,035,000 | $72,904,000 |
| Minority Interest | $758,000 | $2,138,000 | $4,113,000 | $5,505,000 |
| Treasury Stock | $25,000 | $25,000 | $25,000 | $25,000 |
| Additional Paid In Capital | $299,982,000 | $264,780,000 | $217,339,000 | $196,269,000 |
| Capital Stock | $8,000 | $5,000 | $3,000 | $3,000 |
| Common Stock | $8,000 | $5,000 | $3,000 | $3,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $1,486,000 | $1,898,000 | $2,321,000 | $2,079,000 |
| Current Deferred Revenue | $0 | $138,000 | $0 | - |
| Current Capital Lease Obligation | $396,000 | $418,000 | $376,000 | $281,000 |
| Current Accrued Expenses | $1,822,000 | $7,989,000 | $16,430,000 | $8,292,000 |
| Net PPE | $12,719,000 | $11,485,000 | $7,496,000 | $4,210,000 |
| Accumulated Depreciation | $-5,500,000 | $-3,024,000 | $-1,254,000 | $-767,000 |
| Gross PPE | $18,219,000 | $14,509,000 | $8,750,000 | $4,977,000 |
| Leases | $521,000 | $612,000 | $581,000 | $404,000 |
| Other Properties | $16,265,000 | $12,503,000 | $6,885,000 | $3,898,000 |
| Machinery Furniture Equipment | $1,433,000 | $1,394,000 | $1,284,000 | $675,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $2,252,000 | $23,090,000 | $16,724,000 | $0 |
| Non Current Accrued Expenses | - | - | $4,500,000 | $8,000,000 |
| Pensionand Other Post Retirement Benefit Plans Current | - | - | $985,000 | $409,000 |
| Other Inventories | - | - | - | $350,000 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Free Cash Flow | $-44,101,000 | $-61,759,000 | $-36,886,000 | $-24,583,000 |
Operating Activities
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Operating Cash Flow | $-38,218,000 | $-56,014,000 | $-33,009,000 | $-23,134,000 |
| Cash Flow From Continuing Operating Activities | $-38,218,000 | $-56,015,000 | $-33,008,000 | $-23,135,000 |
| Operating Gains Losses | $1,230,000 | $-644,000 | $235,000 | $144,000 |
Investing Activities
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Capital Expenditure | $-5,883,000 | $-5,745,000 | $-3,877,000 | $-1,449,000 |
| Investing Cash Flow | $14,905,000 | $-12,235,000 | $-20,587,000 | $-1,450,000 |
| Cash Flow From Continuing Investing Activities | $14,905,000 | $-12,235,000 | $-20,587,000 | $-1,449,000 |
| Net Other Investing Changes | $10,000 | - | $1,000 | $-1,000 |
Financing Activities
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Issuance Of Capital Stock | $23,009,000 | $27,967,000 | $3,705,000 | $72,827,000 |
| Financing Cash Flow | $16,646,000 | $43,167,000 | $2,696,000 | $79,450,000 |
| Cash Flow From Continuing Financing Activities | $16,646,000 | $43,167,000 | $2,696,000 | $79,448,000 |
| Net Common Stock Issuance | $23,009,000 | $27,967,000 | $3,705,000 | $72,827,000 |
| Common Stock Issuance | $23,009,000 | $27,967,000 | $3,705,000 | $72,827,000 |
| Net Other Financing Charges | - | - | - | $35,000 |
Other
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Repayment Of Debt | $-18,052,000 | $-835,000 | $-1,009,000 | $-658,000 |
| Issuance Of Debt | $11,324,000 | $15,818,000 | $0 | $1,029,000 |
| Interest Paid Supplemental Data | $1,197,000 | $1,759,000 | $36,000 | $340,000 |
| Income Tax Paid Supplemental Data | $0 | $0 | $0 | $0 |
| End Cash Position | $4,896,000 | $11,608,000 | $36,768,000 | $90,230,000 |
| Beginning Cash Position | $11,608,000 | $36,768,000 | $87,711,000 | $35,268,000 |
| Effect Of Exchange Rate Changes | $-45,000 | $-77,000 | $-43,000 | $96,000 |
| Changes In Cash | $-6,667,000 | $-25,083,000 | $-50,900,000 | $54,866,000 |
| Proceeds From Stock Option Exercised | $365,000 | $217,000 | $0 | $6,217,000 |
| Net Issuance Payments Of Debt | $-6,728,000 | $14,983,000 | $-1,009,000 | $371,000 |
| Net Long Term Debt Issuance | $-6,728,000 | $14,983,000 | $-1,009,000 | $371,000 |
| Long Term Debt Payments | $-18,052,000 | $-835,000 | $-1,009,000 | $-658,000 |
| Long Term Debt Issuance | $11,324,000 | $15,818,000 | $0 | $1,029,000 |
| Net Investment Purchase And Sale | $20,778,000 | $-6,490,000 | $-16,711,000 | $0 |
| Sale Of Investment | $51,656,000 | $122,280,000 | $18,945,000 | $0 |
| Purchase Of Investment | $-30,878,000 | $-128,770,000 | $-35,656,000 | $0 |
| Net PPE Purchase And Sale | $-5,883,000 | $-5,745,000 | $-3,877,000 | $-1,449,000 |
| Purchase Of PPE | $-5,883,000 | $-5,745,000 | $-3,877,000 | $-1,449,000 |
| Change In Working Capital | $-6,152,000 | $-16,038,000 | $5,393,000 | $11,834,000 |
| Change In Other Current Liabilities | $-385,000 | $-381,000 | $-275,000 | $0 |
| Change In Other Current Assets | $1,048,000 | $-1,583,000 | $918,000 | $-816,000 |
| Change In Payables And Accrued Expense | $-5,959,000 | $-13,177,000 | $5,629,000 | $12,547,000 |
| Change In Accrued Expense | $-6,358,000 | $-12,710,000 | $4,791,000 | $12,874,000 |
| Change In Payable | $399,000 | $-467,000 | $838,000 | $-327,000 |
| Change In Account Payable | $399,000 | $-467,000 | $838,000 | $-327,000 |
| Change In Inventory | $-466,000 | $-998,000 | $-781,000 | $0 |
| Change In Receivables | $-390,000 | $101,000 | $-98,000 | $103,000 |
| Changes In Account Receivables | $-390,000 | $-319,000 | $0 | - |
| Other Non Cash Items | $1,724,000 | $1,151,000 | $-1,000 | $529,000 |
| Stock Based Compensation | $9,146,000 | $21,337,000 | $19,558,000 | $7,831,000 |
| Unrealized Gain Loss On Investment Securities | $60,000 | $123,000 | $-12,000 | $0 |
| Provisionand Write Offof Assets | $177,000 | $0 | $49,000 | $0 |
| Asset Impairment Charge | $505,000 | $0 | - | - |
| Depreciation Amortization Depletion | $3,571,000 | $2,352,000 | $1,170,000 | $588,000 |
| Depreciation And Amortization | $3,571,000 | $2,352,000 | $1,170,000 | $588,000 |
| Amortization Cash Flow | $205,000 | $205,000 | $205,000 | $38,000 |
| Amortization Of Intangibles | $205,000 | $205,000 | $205,000 | $38,000 |
| Depreciation | $3,366,000 | $2,147,000 | $965,000 | $550,000 |
| Gain Loss On Investment Securities | $-1,551,000 | $-659,000 | - | - |
| Gain Loss On Sale Of PPE | $334,000 | $15,000 | $235,000 | $0 |
| Net Income From Continuing Operations | $-48,479,000 | $-64,295,000 | $-59,401,000 | $-44,060,000 |
| Net Short Term Debt Issuance | - | - | $-1,009,000 | $1,029,000 |
| Short Term Debt Payments | - | - | $-1,009,000 | $-658,000 |
| Short Term Debt Issuance | - | - | $0 | $1,029,000 |
| Sale Of PPE | - | - | $1,000 | - |
| Net Foreign Currency Exchange Gain Loss | - | - | $0 | $144,000 |
| Change In Other Working Capital | - | - | - | - |